Many low concentrations of glycoproteins/glycopeptides in serum or tissue extracts are biomarkers with high clinical sensitivity and specificity, and these biomolecules could provide important information for disease pathogenesis exploration, disease marker discovery, and protein-based drug development. However, it is still a challenge for glycoproteomics to selective isolation and enrichment of glycoproteins/glycopeptides from complex biological samples due to their low concentrations. Currently, nanotechnologies have been widely used for the detection of glycopeptides due to their high sensitivity and specificity.
Nanomaterials possess larger surface areas than bulk materials because of their smaller size. In the context of rapid and sensitive detection, this feature provides additional activation sites for glycopeptide enrichment and unique optical properties. The most promising property of nanomaterials is the degree to which their shape, size, and morphology could be precisely controlled to enhance the electronic, optical, or magnetic capabilities typically required in certain applications. Several nanoplatforms are currently available at CD BioGlyco for the separation of glycopeptides in complex samples with higher sensitivity and specificity.
Fig.1 Overview of different nanomaterials (outside the blue circle) used in combination with biomaterials/biomolecules (inside the blue circle) for various applications (in yellow circle). (Dosekova, 2017)
CD BioGlyco developed strategies to introduce nanoparticles into the glycopeptide enrichment process for selective capture of glycopeptides or glycoproteins, providing glycoprotein enrichment services to our clients.
Many glycoproteomics studies have used mesoporous materials for glycopeptide isolation. CD BioGlyco has developed a variety of mesoporous materials for glycopeptide enrichment with high specificity.
Graphene has the advantages of a large specific surface area and strong absorption capacity. At CD BioGlyco, the surface-functionalized graphene or graphene oxide has been successfully applied in the enrichment of low content glycoproteins.
With a high level of research capability and professionally educated researchers, CD BioGlyco has developed a variety of nanotechnologies and successfully applied them to the detection of low-abundance endogenous glycoproteins/glycopeptides. If you have a demand in this field, please contact us for technical support and we will be delighted to provide you with the best service.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.